Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis
Journal
JHEP reports : innovation in hepatology
Journal Volume
5
Journal Issue
1
Pages
100617
Date Issued
2023-01
Author(s)
Tseng, Cheng-Hao
Chen, Tzu-Haw
Wu, Jia-Ling
Lee, Teng-Yu
Borghi, John A
Nguyen, Mindie H
Hsu, Yao-Chun
Abstract
The risk of serious clinical outcomes following cessation of nucleos(t)ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized. This systematic review and meta-analysis aimed to evaluate current literature on this issue.
Subjects
ALT, alanine transaminase; CHB, chronic hepatitis B; Chronic hepatitis B; ETV, entecavir; HBV, hepatitis B virus; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; NUC, nucleos(t)ide analogues; PT, prothrombin time; TDF, tenofovir disoproxil fumarate; finite therapy; nucleos(t)ide analogue; outcome research
Type
journal article